Flu season gives sales of germ fighters a big boost
Shoppers are scooping up everything from hand sanitizer to disinfecting spray along with cough syrup and other cold remedies.
Reckitt Benckiser, a U.K. conglomerate, has amassed a formidable array of over-the-counter remedies over the past few years, including Mucinex, Cepacol and Delsym, an investment in a $6.5 billion market that Advertising Age says is paying off. The company has gained market share at the expense of Johnson & Johnson (JNJ), maker of Tylenol, which has been hurt by bad publicity stemming from numerous product recalls and federal investigations.
The company says its cough and cold sales totaled just under $100 million for the month ended Dec. 22, a 22% increase from a year earlier.
Reckitt also owns Lysol cleaners, which is surging in popularity. Sales of Lysol disinfectants have risen 17% while liquid-cleaner sales jumped 24% in the four weeks ended Dec. 22, according to Advertising Age, citing Nielsen data. Reckitt's diverse product lineup also includes Dr. Scholl's foot care products, French's mustard and Durex, the world's top-selling condom brand.
Clorox, the largest bleach maker, has seen gains of 12% in disinfectant sales and a 27% increase in wipe sales in the latest 12 weeks for which data is available, the publication says. The company is heavily emphasizing how its product can prevent the spread of germs. Neither company was immediately available for comment.
Closely held GOJO Industries has seen a spike in demand for Purell, the top selling hand sanitizer.
"GOJO anticipates increased demand during winter germ season and adjusts production accordingly as part of our planning process," writes Samantha Williams, a company spokeswoman, in an email, declining to be more specific.
--Jonathan Berr is fighting a nasty bug that his flu shot didn't anticipate. He doesn't own shares of the listed stocks. Follow him on Twitter @jdberr.
More on Money Now
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
While incompetent bosses like Michael Scott and Andy Bernard typically can’t survive in the workplace, office romances are a very real part of corporate culture.
- Southwest Airlines turns less legroom into $773M
- 'American Idol' gets sorry ratings for season finale
- Powerball's wacky sense of humor
- Millions of Facebook's users are actually pets
- Can crowd funding rescue the LA Times?
- Domino's debuts a DVD that smells like pizza
- Average US retirement age climbs to 61
- McDonald's aims to slim down its 145-item menu
- Bathroom reading goes digital with iPad TP stand
[BRIEFING.COM] The S&P 500 ended this week with a bang, roaring to a new all-time high on the back of stronger-than-expected economic data, influential leadership, and an ongoing appreciation for the Fed's monetary policy support.
The bullish bias was evident in premarket action as the S&P futures pointed to a higher start without the benefit of any definitive news catalyst. Stocks indeed benefited from a blast of buying interest at the opening bell on this ... More
More Market News
All hail the bull market, which ended the week with a big rally. But it also is starting to look a little like 1987, which suffered an epic blow-out.